IRVING, Texas– Caris Life Sciences®, a leading innovator in molecular science, and the American Society of Clinical Oncology, Inc. (ASCO®), today announced that Caris is one of the first laboratories to have a test report optimized for ASCO’s Targeted Agent and Profiling Utilization Registry (TAPUR™) Study. The TAPUR Study is evaluating efficacy of treatments based on patients’ tumor genetic profiles. This designation indicates that the company’s proprietary Caris Molecular Intelligence® comprehensive genomic profiling plus (CGP+) tumor profiling platform report is optimized to molecularly identify and report genomic alterations specifically for the TAPUR Study.

Caris Molecular Intelligence, which has performed more than 117,000 clinical cases to date and helps physicians and researchers more effectively evaluate therapy options and clinical trial opportunities, meets the TAPUR Study’s established requirements for optimized reporting. The Caris reports include specific genomic results and simplified data entry by way of an addendum report specifically for TAPUR Study participating centers in a format approved by the ASCO TAPUR Study team. TAPUR sites ordering these tests will be able to easily identify relevant TAPUR variants on a specialized report for potential participants.

“ASCO’s TAPUR Study represents a massive and concerted effort by multiple collaborators and more than 100 clinical sites across 20 states as a ground-breaking trial uniquely focused on learning from the use of 15 approved targeted cancer therapies matched to tumor genomics for an effective precision medicine strategy,” said John Marshall, MD, Chief Medical Officer of Caris Life Sciences. Dr. Marshall is also the Associate Director for Clinical Care for the Georgetown Lombardi Comprehensive Cancer Center and the Chief of the Division of Hematology-Oncology at MedStar Georgetown University Hospital in Washington, D.C. “We are excited to participate by providing optimized Caris Molecular Intelligence test reports that effectively inform clinicians on patients’ tumor profiles at the TAPUR Study centers to guide more precise and individualized patient treatment decisions, and we look forward to furthering the success of this significant trial.”
“We are excited to work with Caris Life Sciences on the TAPUR Study,” said Richard L. Schilsky, MD, FACP, FASCO, TAPUR study principal investigator. “TAPUR is designed to identify signals of drug activity for targeted anti-cancer drugs used outside of their approved indications. The optimized Caris test report will help TAPUR clinical sites determine who is eligible in a much more expedient fashion.”

Health IT Homepage